CARA - Enteris BioPharma secures $2.5M milestone payment from Cara Therapeutics

SWK Holdings' (SWKH) subsidiary, Enteris BioPharma, has received a milestone payment of $2.5M from Cara Therapeutics (CARA) related to the license agreement for Peptelligence oral formulation technology utilized in Oral KORSUVA, the oral formulation of CR845/difelikefalin.SWK is entitled to receive $1.5M of this payment per the contractual splits agreed to in the Enteris acquisition agreement, as well as eligible to receive additional potential milestone payments over the next several quarters, subject to the achievement of certain development milestones for Oral KORSUVA.Cara also said it plans to complete an End of Phase 2 Meeting with the FDA in Q1 of 2021 and that it intends to initiate the safety portion of the Phase 3 program during this quarter.

For further details see:

Enteris BioPharma secures $2.5M milestone payment from Cara Therapeutics